
# Path Af

# Problem Statement

Currently pathologists do not fully leverage Al based decision support software to provide **timely** and **accurate** diagnosis of leukemia **across the globe**.

# Lack of Pathologists




## First Market


Childhood leukemia, the most prevalent form of childhood cancer, represents 24.9 % of all new childhood cancer cases



# **Current Process**



# Underdiagnosis



# Why have current solutions failed?

# Clinical pathologists don't want to use the current DSS systems.

- "Pathologists do not currently support the idea of using automated diagnosis to make evaluations."
- Josh Wong MD, Pathology Resident

# Why have current solutions failed?

### Current technology is very expensive.

- "Now, our technology is not advanced enough to provide easy diagnosis with low cost options"
- Roman Karp MD, Pathserve Tissue Bank

Solution

# Path Af




...

Jose
Patient ID

Meet Jose

# Our Model




# **Current Application**



- Image Diagnosis Confidence level
- Regions of interest

# Business Model and Projected Growth

- Insurance providers and patient will pay for the services on a test-by test methodology
- Costs=\$35
- Margin=\$250
- Profit=\$215/scan
- 500,000 clinical lab tests in leukemia in USA
- 107.5 M in potential profits






#### **PATIENTS**



#### **PATIENT REPORT**



# Cross Platform Integration





### About the Team



Abhijit Bhattaru Radiology Researcher Penn Med



John Harman

Mathematics &

Computer Vision

Depaul University



Andrew Hudak
Research Associate
Broad Institute of MIT
and Harvard



Joseph Chen
Computer Vision
Specialist



Basia Jackson Public Health Scholar